Please sign in to follow a disease.
Could a drug combo make sleep apnea scopes easier?
NCT ID NCT06784479
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two sedatives, remimazolam and propofol, works better than propofol alone or with midazolam during a procedure called drug-induced sleep endoscopy (DISE) for people with obstructive sleep apnea. The goal is to see if the combo leads to more successful sedation with fewer side effects. About 174 adults with sleep apnea will take part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Remimazolam and Propofol
- What this could lead to
- If successful, this could identify a safer, more effective sedation method for diagnosing sleep apnea, improving patient comfort and procedure success.
- What could go wrong
- This is a small, single-center phase 4 trial focused on sedation during a diagnostic procedure, not a treatment for sleep apnea itself. Results may not apply to other settings or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
174 people
The number who actually took part.
- Started
-
Mar 2025
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients diagnosed with sleep apnea hypopnea syndrome were included Exclusion Criteria: * Patients were excluded if they had nasal obstruction, significantly deviated nasal septum, nasal turbinate hypertrophy, or nasal polyps. Patients with uncontrolled heart failure, renal insufficiency, diabetes, or hyperthyroidism were also excluded. Patients were also excluded if taking medications that could affect upper airway muscle function, such as ben- zodiazepines and muscle relaxants.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea (OSA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Respiratory Endoscopy Center of Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New mask aims to make sleep apnea therapy easier to live with
- Can a weekly phone call keep sleep apnea patients on CPAP?
- A smart neck brace may replace CPAP for sleep apnea
- A blood test for liver trouble may flag hidden risk in sleep apnea patients
- Blood oxygen dips may reveal who stays on CPAP
- Can a simple questionnaire improve sleep apnea treatment?